Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 4/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718666 | 0.82 | TRPM8 (0.50) | TRPM8PTGDR2KDM4EGAAKMT2A | |
| SCHEMBL3915148 | 0.81 | CMA1 (0.38) | TRPM8MAPTPPARG | |
| SCHEMBL718494 | 0.79 | TRPM8 (0.57) | TRPM8S1PR3 | |
| SCHEMBL717743 | 0.79 | TRPM8 (0.57) | TRPM8S1PR3 | |
| SCHEMBL718645 | 0.79 | TRPM8 (0.57) | TRPM8S1PR3 | |
| SCHEMBL715446 | 0.78 | TRPM8 (0.46) | TRPM8GAAKMT2ALMNAMAPT | |
| SCHEMBL717818 | 0.77 | TRPM8 (0.43) | TRPM8PTGDR2KDM4EGRM4GAA | |
| SCHEMBL717399 | 0.75 | TRPM8 (0.44) | TRPM8S1PR3 | |
| SCHEMBL719510 | 0.75 | TRPM8 (0.40) | TRPM8 | |
| SCHEMBL716272 | 0.74 | TRPM8 (0.44) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| EP-2029614-B1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | disclosed |
| US-7897781-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| EP-2029614-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007134107-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027029-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PTGDR2 701/4885KDM4E 2229/4885 |
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PTGDR2 701/4885KDM4E 2229/4885 |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PTGDR2 701/4885KDM4E 2229/4885 |
| US-20080287398-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PTGDR2 701/4885KDM4E 2229/4885 |
| US-20140100194-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PTGDR2 701/4885KDM4E 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.